NCT06006845招募中不适用
When to Initiation Antitumor Therapy for Tumor Patients With COVID19 Infection
The Seventh Affiliated Hospital of Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年12月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Re-infection of COVID-19
研究概览
简要总结
The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19. The main questions aims to answer are:
- Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy.
- Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19.
- How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patients
Participants will be asked to answer the question about:
- the severity and duration of COVID-19 symptoms
- the date of diagnosis of COVID-19
- the date of negative nucleic acid test
- the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022 to May
- •COVID-19 was confirmed by antigen testing or nucleic acid testing.
- •Tumor was confirmed by pathology.
- •Patients received systemic antitumor therapy after infected with COVID-19.
排除标准
- •COVID-19 was not confirmed by antigen testing or nucleic acid testing
- •Tumor was not confirmed by pathology
- •Patients did not receive systemic antitumor therapy
- •Patients died before receiving systemic antitumor therapy
结局指标
主要结局
Re-infection of COVID-19
时间窗: 28 days after antitumor therapy
Antigen testing or nucleic acid testing positive for COVID-19
Incidence of adverse events after antitumor therapy
时间窗: 28 days after antitumor therapy
Incidence of adverse events after antitumor therapy, including hematologic toxicity,gastrointestinal adverse event, hepatobiliary adverse events, etc.
次要结局
- Clinical manifestations of COVID-19 in tumor patients(Until nucleic acid testing turn negative)
研究者
Wang Bo
Professor
The Seventh Affiliated Hospital of Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second RelapsePatients With Multiple Myeloma Experiencing aFirst or Second RelapseNCT01217203Innate Pharma15
已完成
2 期
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)Facial Cutaneous Squamous Cell Carcinoma in SituNCT06159842The Center for Clinical and Cosmetic Research32
招募中
2 期
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)Cutaneous Squamous Cell CarcinomaNCT06577311The Center for Clinical and Cosmetic Research20
已完成
1 期
Biodistribution and Dosimetry of 99mTc-DuramycinHealthy VolunteersNCT05177640University Hospital, Antwerp6
已完成
1 期
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell CarcinomaUrinary Bladder NeoplasmsRenal Cell CarcinomaNCT02619253Nabil Adra52